# Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency

> **NCT00811785** · PHASE3 · COMPLETED · sponsor: **Cyprium Therapeutics, Inc.** · enrollment: 93 (actual)

## Conditions studied

- Menkes Disease
- Occipital Horn Syndrome
- Unexplained Copper Deficiency

## Interventions

- **DRUG:** Copper Histidine

## Key facts

- **NCT ID:** NCT00811785
- **Lead sponsor:** Cyprium Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02-27
- **Primary completion:** 2020-08-28
- **Final completion:** 2020-08-28
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2020-11-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00811785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00811785, "Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00811785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*